Efficacy and safety of Oxalobacter formigenes to reduce urinary oxalate in primary hyperoxaluria

Bernd Hoppe, Jaap W. Groothoff, Sally Anne Hulton, Pierre Cochat, Patrick Niaudet, Markus J. Kemper, George Deschênes, Robert Unwin, Dawn Milliner

Research output: Contribution to journalArticle

88 Scopus citations

Abstract

Background. Primary hyperoxaluria (PH) is a rare genetic disease, in which high urinary oxalate (Uox) cause recurrent kidney stones and/or progressive nephrocalcinosis, often followed by early end-stage renal disease, as well as extremely high plasma oxalate, systemic oxalosis and premature death. Oxalobacter formigenes, an anaerobic oxalate degrading bacterium, naturally colonizes the colon of most humans. Orally administered O. formigenes (Oxabact) was found to significantly reduce urine and plasma oxalate. We aimed to evaluate its effect and safety in a randomized, double-blind, placebo-controlled multicenter study.Methods. Oral Oxabact was given to PH patients (>5 years old, Uox > 1.0 mmol/1.73m 2/day, glomerular filtration rate (GFR) > 50 mL/min) at nine PH referral sites worldwide. Primary endpoint was the change from baseline in Uox (mmol/1.73m 2/day) after 24 weeks of treatment (>20% reduction).Results. Of the 43 subjects randomized, 42 patients received either placebo (23 subjects) or Oxabact (19 subjects). The change in Uox was <20% and not different between groups (P = 0.616). Ad hoc analysis was performed in 37 patients compliant with medication and urine processing. Change in Uox was -19% in subjects given Oxabact and -10% in placebo, (P = 0.288), but -21 and -7% with Uox expressed as molar creatinine ratio (Ox:Cr, mmol/mol, P = 0.06). Reduction of Ox:Cr was more obvious for patients with higher baseline values (>160 mmol/mol, Oxabact -28%, placebo -6%; P < 0.082). No serious adverse events were reported.Conclusion. Oxabact was safe and well tolerated. However, as no significant change in Uox was seen, further studies to evaluate the efficacy of Oxabact treatment are needed.

Original languageEnglish (US)
Pages (from-to)3609-3615
Number of pages7
JournalNephrology Dialysis Transplantation
Volume26
Issue number11
DOIs
StatePublished - Nov 2011

    Fingerprint

Keywords

  • efficacy
  • Oxalobacter formigenes
  • primary hyperoxaluria
  • safety
  • treatment

ASJC Scopus subject areas

  • Nephrology
  • Transplantation

Cite this

Hoppe, B., Groothoff, J. W., Hulton, S. A., Cochat, P., Niaudet, P., Kemper, M. J., Deschênes, G., Unwin, R., & Milliner, D. (2011). Efficacy and safety of Oxalobacter formigenes to reduce urinary oxalate in primary hyperoxaluria. Nephrology Dialysis Transplantation, 26(11), 3609-3615. https://doi.org/10.1093/ndt/gfr107